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Abstract
Objective: Children treated with stimulant medication for attention deficit hyperactivity disorder (ADHD) often lose
weight. It is important to understand the implications of this during growth. This prospective study was designed
to quantify the changes in body composition and markers of bone metabolism on starting treatment.
Methods: 34 children (29 boys) aged 4.7 to 9.1 years newly diagnosed with ADHD were treated with
dexamphetamine or methylphenidate, titrating the dose to optimise the therapeutic response. Medication was
continued for as long as clinically indicated. Body composition and bone density (dual-energy X-ray
absorptiometry) were measured at baseline, 6 months and 3 years; changes were analysed in Z-scores based on
data from 241 healthy, local children. Markers of bone turnover were measured at baseline, 3 months and 3 years.
Results: Fat loss of 1.4±0.96kg (total fat 5.7±3.6 to 4.3±3.1kg, p<0.001) occurred in the first 6 months. There were
significant reductions over 3 years in the sex and height corrected Z-scores for lean tissue, bone mineral content,
bone mineral density and ratio of central to total fat (−0.84±0.86, p=0.003; -0.55±0.31, p<0.0001; -0.41±0.28,
p<0.0001 and −0.55±0.62, p=0.006 respectively). Propeptide of type I collagen indicated a significant reduction in
bone turnover after 3 months (564±202 to 458±96ng/ml, p=0.019), which was fully recovered after 3 years
(619±276ng/ml).
Conclusions: Stimulant medication was associated with early fat loss and reduced bone turnover. Lean tissue
including bone increased more slowly over 3 years of continuous treatment than would be expected for
growth in height. There was long-term improvement in the proportion of central fat for height. This study
shows that relatively minor reductions in weight on stimulant medication can be associated with long-term
changes in body composition. Further study is required to determine the effects of these changes on adult
health.
Keywords: Body composition, Attention deficit hyperactivity disorder, Stimulant medication, Bone
biochemistry, Weight loss
* Correspondence: alison.poulton@sydney.edu.au
1Department of Paediatrics, Sydney Medical School Nepean, The University
of Sydney, Penrith, NSW, Australia
Full list of author information is available at the end of the article
© 2012 Poulton et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Poulton et al. International Journal of Pediatric Endocrinology 2012, 2012:30
http://www.ijpeonline.com/content/2012/1/30
Background
The stimulant medications dexamphetamine and me-
thylphenidate are used for the treatment of children with
attention deficit hyperactivity disorder (ADHD) because
they reduce the level of hyperactivity and enhance the
attention span. Weight loss and reduced height velocity
are well-recognized collateral effects [1-3], particularly in
the first 6 months of treatment. In a previous study we
demonstrated that the growth rates for height and
weight progressively normalized over 2–3 years on treat-
ment, but the period of slower growth was associated
with long-term reductions in the age and sex corrected
Z-scores for height and weight [4]. These observations
raise the following important questions: what is the na-
ture of the tissue being lost and what is the effect on
bone development?
The aims of this prospective study were to monitor
growth in children with ADHD starting treatment with
stimulant medication and to look for changes in body
composition and markers of bone metabolism. The hy-
potheses informing the study design were (1) that acute
changes in hormones and bone biomarkers during
weight loss would be observed in the first 3 months of
treatment; (2) that changes in body composition would
be detectable after 6 months and (3) a new steady state
of normal growth on stimulant medication would be
reached after 3 years of continuous treatment.
Methods
Design and setting
This was a clinic based, prospective, cohort study with
up to three years follow up. Recruitment was mainly
from a single pediatric private practice in western
Sydney; two other practices each contributed one pa-
tient. Recruitment began in July 2003 and continued
until April 2008. Ethical approval was granted by the
Human Research Ethics Committee of Wentworth
Area Health Service in western Sydney (02/013).
Study participants
We invited parents of consecutive children aged <9 years
who were newly diagnosed with ADHD and had a clin-
ical indication for starting treatment with stimulant
medication to enroll their children in the study. The
diagnosis of ADHD was based on clinical interview with
additional information on functioning at school or pre-
school. All children met the diagnostic criteria of the
American Psychiatric Association (DSM-IV) [5]. Chil-
dren with a history of previous treatment with psycho-
tropic medication or with medical conditions likely to
impact on growth were excluded. Informed consent was
given by the parents of all participants; all participating
children assented to the study.
Treatment protocol
All children were initially trialed on immediate release
methylphenidate or dexamphetamine; some children
were subsequently prescribed extended release formula-
tions. Treatment allocation was based on cost, with dex-
amphetamine being the preferred medication until
methylphenidate also became subsidised. The dose was
titrated to give the maximum therapeutic benefit at the
lowest possible dose of medication, in line with recom-
mended practice parameters [6]. Children who were
stable and functioning well on stimulant medication
were reviewed every 6 months and the dose adjusted
when clinically indicated. This decision was based on
parental reports of the child’s functioning, the child’s
opinion, school reports and other documentation from
the school, including the IOWA Conner’s rating scale
[7]. If at any stage there was no clear advantage to
stimulant medication and the child was functioning ad-
equately, medication was ceased and the child’s func-
tioning reassessed off medication. No further data were
collected on children who had ceased medication.
Data collection
We measured height to the nearest 1mm using a wall
mounted stadiometer and weight to the nearest 0.1kg
using electronic scales. All measurements were made
without shoes or outdoor clothing. Measurements were
taken at every clinic visit and without prior reference to
any previous measurements.
Body mass index (BMI) was calculated as the weight
in kg divided by the square of the height in meters and
the height, weight and BMI were corrected for age and
sex by conversion to Z-scores based on Centers for Dis-
ease Control and Prevention (CDC) reference data [8].
Dual-energy X-ray absoptiometry (DXA) scans of the
Total Body and lumbar spine were performed using a
GE-Lunar Prodigy (GE Lunar Corp, Madison, WI). Daily
quality assurance and quality control (spine phantom in
water bath) were performed.We measured total body
(including head) and body subregions (arms, legs, trunk)
lean tissue and fat masses, bone mineral content (BMC),
bone mineral density (BMD) and fat distribution (ratio
of central to total fat; fat C/T). For estimation of the
central (truncal) fat, the trunk region (which includes
the pelvis) was delineated by a single assessor using
standard manufacturer analysis guidelines. The assessor
(JB) has shown good inter-rater reliability with a col-
league [9]. Lumbar spine (L2-L4), BMD and BMC were
also determined. Raw DXA values were converted into
Z-scores using DXA control data.
DXA control data measured using a Lunar DPX (GE
Lunar Corp, Madison, WI) were available from 241
healthy children (105 boys), aged 4.2-12.0 years (mean
8.54±1.93 years). Parents of these children had
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consented for them to have a single DXA to provide
reference data for research purposes. Although there
was no direct comparison of the Lunar DPX and the
Lunar Prodigy used for the subjects, our data from 97
children comparing another Lunar Prodigy with the
Lunar DPX showed no significant differences in BMC or
BMD. There were small differences in lean tissue mass
(mean 28.6 vs 29 kg), and fat (mean 11.4 vs 12.3 kg) but
the results were all highly correlated (all r2 > 0.98).
Blood samples were collected unmedicated after an
8 hour overnight fast. The following bone turnover
markers and calciotropic hormones were measured:
osteocalcin, 25-hydroxy vitamin D, parathyroid hormone
(PTH), amino-terminal propeptide of type I collagen
(P1NP) and C-telopeptides (CTX). In addition, appetite
regulating hormones (leptin and ghrelin) and the growth
hormone dependent growth factors insulin-like growth
factor 1 (IGF-1) and insulin-like growth factor binding
protein 3 (IGFBP-3), together with fasting insulin, glu-
cose albumin, pre-albumin, ferritin and transferrin were
measured to look for changes in growth and appetite
regulation and for biochemical evidence of undernutrition.
Vitamin D and osteocalcin were analysed by chemilumin-
escence immunoassays on a Diasorin Liaisonanalyzer
(Diasorin, Italy). CTX and P1NP were measured with
commercial electrochemiluminescence immunoassays
(Modular E170, Roche Diagnostics, Australia). Albumin
was analysed using an automated colorimetric assay us-
ing a Vitros Fusion analyser (Ortho Clinical Diagnostics,
Australia). Pre-albumin used an immunoturbid metric
assay on an Integra (Roche Diagnostics, Australia). Ferritin
was assayed using an immunometric assay on a Vitros ECI
(Ortho Clinical Diagnostics, Australia). Iron deficiency was
defined as ferritin <20 ug/L. Transferrin used the TRNF
method, which is a quantitative turbid metric assay (Di-
mension Xpand, Siemens Medical Solutions Diagnostics
Pty Ltd, Sydney, Australia). Glucose was analysed using
routine laboratory procedures. Leptin and total ghrelin
levels were analysed using radioimmunoassay (Millipore,
MA) and insulin by chemiluminescence (IMMULITE
2000W, Siemens Medical Solutions Diagnostics Pty Ltd,
Sydney, Australia). PTH, IGF-I and IGFBP-3 were mea-
sured by ELISA using the IMMULITE 1000W analyser
(Siemens Medical Solutions Diagnostics Pty Ltd, Sydney,
Australia).
Sample size calculations
These were based on the growth data from our previous
study [4]. The estimated sample sizes required to detect
a change in height Z-score with 90% power at 5% two
sided significance were 16 and 11 after 6 months and
3 years respectively; for weight Z-score these were 8 and
13 respectively. Therefore we aimed to recruit 30 chil-
dren, to allow for 50% attrition at 3 years.
Outcome measures
Growth
Growth was analyzed as changes in height, weight and
BMI Z-scores.
Body composition
Body composition was analysed as follows:
1. Longitudinal changes in lean tissue, fat, BMC, BMD
and fat distribution (fat C/T).
2. Cross sectional comparison of lean tissue, fat, BMC,
BMD and fat C/T at each timepoint with the DXA
control data, controlling for age, sex and height.
3. Longitudinal changes in lean tissue, fat, BMC, BMD
and fat C/T at 6 months and 3 years in relation to
growth in height using sex and height corrected Z-
scores based on the DXA control data. Height was
used instead of age as we considered this to be the
more clinically relevant measure if height was not
changing proportionally with age due to stimulant
associated changes in the height velocity.
Statistical analysis
We used paired t-tests for longitudinal data analysis and
independent sample t-tests for cross sectional compari-
son. The DXA data from the subjects were compared to
the DXA control data using general linear modeling with
age, sex and height as independent variables. Correla-
tions between variables used the Pearson correlation. All




Thirty-four children aged 4.7 to 9.1 years (mean 7.3±1.3
years, 29 boys) were recruited. Of these, 29 had baseline
DXA scans and 31 had baseline blood tests (Figure 1).
All met a DSM-IV diagnosis of ADHD and the majority
(78%) had hyperactivity-impulsivity as well as inattention
(combined type). The majority of children were treated
with methylphenidate: at 6 months there were 23 on
methylphenidate (mean 24.3±6.2 mg/day; 0.91±0.19 mg/
kg/day) and 7 on dexamphetamine (mean 11.1±2.8 mg/
day; 0.42±0.08 mg/kg/day). The attrition rate for investi-
gations was 53% (18/34) at 3 years. Eight of these chil-
dren were still being treated with stimulant medication
and had growth data available; the remaining 10 (29% of
the cohort) had either ceased medication (n=3), had
moved away (n=1) or were otherwise lost to follow up
(n=6). There were no significant differences in age or
growth parameters between those who did and those
who did not complete their investigations, therefore the
growth data of all the children who remained on treat-
ment have been included in the tables and figures.
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Growth rates
At baseline the mean Z-scores for height, weight and
BMI were 0.49 ± 0.99, 0.62 ± 0.97 and 0.52 ± 1.02 re-
spectively (Table 1). Over 3 years there were significant
reductions from baseline in the Z-scores for height,
weight and BMI (all p<0.001). This was predominantly
due to slower growth in the first 6 months (Table 2); the
growth rate showed normalization with time (p<0.01
and p<0.001 for the difference in the rate of change from
0–6 months and from 6 months to 3 years for height
and weight Z-scores respectively). The growth pattern is
illustrated in Figure 2.
Body composition
Baseline DXA data were available for 29 children,
repeated at 6 months (median 6.8 months, mean 7.3±1.8
months) in 24 (19 boys) and at 3 years (median 2.9
years, mean 2.7±0.6 years) in 14 (12 boys).
Longitudinal changes in tissue mass
In the first 6 months the children lost 2.2±3.6% of their
total tissue mass (p=0.007), which equated to an average
loss of 0.65 ± 1.07 kg of tissue (p=0.009). This was asso-
ciated with a significant reduction in their fat mass (5.7±3.6
to 4.3±3.1kg, change −1.40 ± 0.96 kg, p<0.001) (Figure 3).
The average fat loss was greater than the weight
loss because of a significant rise in lean tissue (20.4±3.0 to
21.2±3.1kg, change 0.76±0.64 kg, p<0.001). Total BMC
increased significantly (1.02±0.20 to 1.06±0.20kg,
change 0.04±0.03 kg, p<0.001). BMD increased signifi-
cantly in the arms (0.61±0.04 to 0.62±0.04 kg/m2,
Figure 1 Number of subjects and attrition in each part of the study.
Table 1 Growth data of the subjects compared to the controls
All subjects All subjects All subjects DXA Controls
Baseline n=34 6 months n=30 36 months n=24 n=241
Mean ± sd Range Mean ± sd Range Mean ± sd Range Mean ± sd Range
Age (years) 7.27 ± 1.30*** 4.71-9.12 7.99 ± 1.21* 5.33-9.64 10.49 ± 1.22*** 7.87-12.21 8.54 ± 1.93 4.02-11.99
Height (cm) 125.5 ± 9.1* 110.3-142.2 128.6 ± 9.2 112.6-145.6 140.6 ± 9.0*** 125.5-156.0 130.5 ± 12.7 94.5-161.6
Weight (kg) 27.0 ± 6.1 19.1-42.1 26.8 ± 5.9 19.3-42.2 34.4 ± 8.4** 25.0-56.0 29.0 ± 8.2 13.1-60.4
BMI (kg/m2) 17.0 ± 2.3 13.7-23.7 16.1 ± 2.3 12.9-23.0 17.3 ± 3.1 13.9-26.5 16.7 ± 2.2 13.3-25.6
Height Z-score 0.49 ± 0.99** −1.08-3.02 0.22 ± 0.95 −1.19-2.76 −0.07 ± 0.81 −1.18-1.67 −0.06 ± 0.97 −2.24-2.07
Weight Z-score 0.62 ± 0.97*** −1.60-2.95 0.04 ± 1.04 −1.86-2.63 −0.12 ± 0.87 −1.48-1.58 −0.05 ± 0.92 −2.25-2.23
BMI Z-score 0.52 ± 1.02** −1.88-2.31 −0.17 ± 1.21 −2.92-2.04 −0.16 ± 1.11 −2.45-1.97 0.03 ± 0.88 −2.11-2.09
*p<0.05; **p<0.01; ***p<0.001 compared to DXA controls (independent samples t-test).
DXA: Dual-energy X-ray absorptiometry.
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change 0.006±0.012 kg/m2, p=0.023) but there was no
significant change in the total body, trunk, legs or
lumbar spine. Over the period from baseline to
3 years there were significant increases in all tissues.
Cross sectional comparison with DXA control data
controlling for age, sex and height using general linear
modeling
After controlling for age, sex and height the subjects’
BMD and fat C/T were significantly greater than the
DXA controls’ at all time points (Table 3). The subjects’
BMC was significantly greater at baseline but there was
no significant difference at 6 months or 3 years. The
subjects’ lean tissue mass was significantly lower than
the DXA controls at 3 years. There was no significant
difference at any stage between subjects and DXA con-
trols in their total fat corrected for age, sex and height.
Table 3, as well as showing the comparison of the body
composition and bone density of the subjects and con-
trols, also indicates the direction of change with time.
For example lean tissue increased with age in the con-
trols but decreased in the subjects and after 3 years of
treatment the subjects had significantly lower sex, height
and age corrected lean tissue than the controls.
Longitudinal changes in sex and height corrected Z-scores
After 6 months the sex and height corrected Z-scores
for BMC, BMD, fat and fat C/T all showed signific-
ant reductions (0.52±0.80 to 0.34±0.79, p<0.001;
0.54±0.79 to 0.39±0.85, p=0.010; 0.76±1.13 to
−0.23±0.97, p<0.000001 and 1.10±0.80 to 0.65±0.88,
p=0.003 respectively) but there was no significant
change in the lean tissue Z-score for height and sex
(−0.05±0.96 to 0.19±1.02, p=0.11). After 3 years the sex
and height corrected Z-scores for lean tissue, BMC,
BMD and fat C/T all showed significant reductions from
their baseline values (0.09±0.89 to −0.74±1.10, p=0.003;
0.57±0.60 to 0.02±0.66, p<0.0001; 0.62±0.67 to
0.21±0.70, p<0.0001; and 1.01±0.80 to 0.46±1.06, p=0.006
respectively). By contrast at 3 years the Z-score for the fat
mass for height was not significantly different from baseline
(0.41±1.06 to 0.26±1.29, p=0.62).
Blood tests
Of 31 children who provided baseline blood samples, 25
(81%) provided repeat samples after 3 months and 14
(48%) after 3 years (Table 4). At baseline 10 children
(32%) had iron deficiency; these children showed a sig-
nificant rise in ferritin over 3 years (p=0.04). In the first
3 months there were significant falls in concentrations
of leptin and P1NP (4.45±4.03 ng/ml to 2.73±2.03 ng/ml,
p<0.010 and 554±176 ng/ml to 458±93ng/ml, p=0.019
respectively) and a significant rise in albumin (45.1 ±
3.7 g/L to 46.5±3.2 g/L, p<0.027). Concentrations of
osteocalcin, CTX, IGF-1 and IGFBP-3 increased over
3 years (50.9±21.9 ng/mL to 80.9±22.2 ng/mL, p=0.003;
0.545±0.205 pg/mL to 0.886±0.518 pg/mL, p=0.038;
19.7±7.3 nmol/L to 31.1±18.0 nmol/L, p=0.041; and
4.07±1.08 ug/mL to 5.82±2.75 ug/mL, p=0.034 re-
spectively). There were no significant changes in fast-
ing levels of vitamin D, PTH, prealbumin, ferritin,
transferrin, insulin, glucose or ghrelin.
We found no significant differences between the
effects of dexamphetamine and methylphenidate on any
of the parameters measured.
0–3 month changes predicting subsequent changes in
body composition variables
Changes in the concentrations of IGF-1 and IGFBP-3 in
the first 3 months were significant predictors of the
changes in lean tissue from 6 months to 3 years (r=0.72,
p=0.028 and r=0.74, p=0.022 respectively); in addition
the changes in IGFBP-3 also correlated inversely with
the subsequent changes in fat mass (r=−0.95, p<0.001).
The changes in osteocalcin in the first 3 months cor-
related with the changes in BMD from 6 months to
3 years (r=0.77, p=0.026).
Table 2 Growth rates of the subjects over different time periods on medication
Time period
(months: mean ± SD)
Pre-treatment 0-6 months 6-12 months 12-24 months 24-36 months
(16.6 ± 9.4) (6.3 ± 1.5) (7.3 ± 2.0) (11.4 ± 2.1) (10.9 ± 2.5)
n=11 n=30 n=30 n=28 n=24
Height velocity (cm/year) 6.5 ± 1.1 4.3 ± 1.9 4.5 ± 1.3 4.7 ± 1.2 5.3 ± 1.2
Weight velocity (kg/year) 2.7 ± 1.8 −1.5 ± 2.8 3.2 ± 3.1 2.9 ± 2.3 4.1 ± 2.3
Change in BMI/year 0.08 ± 0.86 −2.09 ± 1.89 0.81 ± 1.74 0.45 ± 1.05 0.83 ± 0.95
Δ Height Z-score/year −0.04 ± 0.17 −0.32 ± 0.38*** −0.22 ± 0.21*** −0.11 ± 0.19** −0.02 ± 0.17
Δ Weight Z-score/year −0.09 ± 0.36 −1.04 ± 0.74*** 0.03 ± 0.63 −0.13 ± 0.27* 0.06 ± 0.29
Δ BMI Z-score/year −0.08 ± 0.44 −1.29 ± 0.94*** 0.26 ± 0.96 −0.10 ± 0.39 0.12 ± 0.43
*p<0.05; **p<0.01; ***p<0.001 for the change in Z-score over the time period using single sample t-tests against a test value of zero.
Statistical analysis was applied to the changes in Z-scores only and used single sample t-tests with a test value of zero.
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Discussion
To our knowledge this is the first study to utilize DXA
for determining the actual and relative losses of tissue
when children start treatment with stimulant medication
and to relate these to biochemical changes. The serum
concentrations of leptin were decreased after starting
treatment, correlating with the significant loss of fat
mass. There was an early relative decrease in bone mass
associated with a reduction in bone formation, with a
significant recovery after three years of treatment asso-
ciated with a recovery in cell coupling and bone turn-
over. In contrast, serum concentrations of vitamin D
and PTH remained stable. At baseline the ADHD sub-
jects had greater central adiposity than the DXA con-
trols. The proportion of central fat declined on
treatment, in parallel with progressive reductions in
weight and BMI Z-scores. Over 3 years the lean tissue
including bone increased more slowly than would be
expected for growth in height.
The main strength of this study is in the combination
of body composition analysis with biochemical para-
meters and regular, careful monitoring of height and
weight. This methodology allowed us to relate the
changes in growth parameters and body composition
with our characterization of changes in serum metabolic
markers, calciotropic hormones and bone turnover mar-
kers. However, the study was limited by the small num-
ber of timepoints for evaluating longitudinal changes.
Another limitation of the study is the relatively small
size of the cohort, which may have been the reason that
the reductions in IGF-1, IGFBP-3 and CTX at 3 months
did not reach statistical significance. This study is also
limited by the lack of longitudinal control data. Al-
though there were no untreated children with ADHD
Figure 2 Growth chart showing the average height and weight calculated from the changes in Z-scores. The error bars denote the
standard deviation of the change in Z-scores going forwards and backwards from the baseline data, standardised for the average baseline age.
The data show initial weight loss with simultaneous slowing of the height velocity on starting stimulant medication. Reference data: Centres for
Disease Control and Prevention (CDC) 2000; mean ± 2SD.
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for longitudinal comparison, we were able to show sig-
nificant reductions in the rates of increase in height and
weight on starting treatment. This is consistent with
stimulant associated reductions in the growth rates [4].
Another limitation is that the subjects and controls were
not analysed on the same DXA machine. However, we
principally used the controls’ data as a reference for lon-
gitudinal analysis of changes within subjects. For this,
minor differences between machines would be far less
important than they would be for the direct comparisons
Figure 3 Percentage change in components of body composition. BMC: bone mineral content; BMD: bone mineral density 6 months n=23;
3 years n=14 *** p<0.001; ** p<0.01; * p<0.05 from baseline, paired t-test. There was a significant reduction in fat mass and significant increases
in lean tissue and BMC in the first 6 months. Over 3 years there were significant increases in lean tissue, BMC, BMD and fat.
Table 3 Body composition of the subjects at different times compared to the controls
Subjects DXA Controls
Baseline: n=29 (24 boys) n=241 (105 boys)
6 months: n=23 (19 boys)
36 months n=14 (12 boys)
LS mean Compared to DXA controls LS mean Comparator
Lean tissue (kg) Baseline 20.82 p=0.22 21.36
6 months 20.79 p=0.14 21.51
36 months 20.00 p=0.007 21.72
BMC (kg) Baseline 1.053 p=0.04 1.001
6 months 1.052 p=0.13 1.011
36 months 1.050 p=0.46 1.024
BMD (kg/m2) Baseline 0.891 p<0.0001 0.849
6 months 0.889 p=0.0002 0.851
36 months 0.889 p=0.006 0.854
Total fat (kg) Baseline 6.28 p=0.24 5.55
6 months 4.84 p=0.25 5.62
36 months 5.35 p=0.69 5.71
Central/total fat Baseline 0.421 p<0.0001 0.349
6 months 0.390 p=0.0009 0.350
36 months 0.383 p=0.047 0.352
LS Mean: Least squares mean and p values compared to DXA controls using general linear model controlling for effects of age, sex and height.
DXA: Dual-energy X-ray absorptiometry.
Statistically significant p-values are given in bold type.
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of the subjects with the controls. Using linear modeling
controlling for age meant that all the controls could be
compared with the subjects at every time point, maxi-
mising statistical power. It was not possible to evaluate
the changes in relation to physical maturation as only
one girl and one boy had entered puberty at the 3 year
review. When we included stage of puberty in the ana-
lysis there was no significant effect, which we attribute
to insufficient numbers.
There has been one previous cross sectional study in-
vestigating BMD and bone turnover in 10 boys who had
been taking methylphenidate for 1–2 years compared to
10 healthy boys matched for age, height and weight [10].
The boys had had no changes in growth percentiles on
treatment. This study reported no significant differences
in BMD, serum bone-specific alkaline phosphatase or in
urinary deoxypyridinoline in the study group as com-
pared to the controls. In contrast, using more specific
methods to quantify bone turnover, we have identified a
significant decrease in bone formation (P1NP) during
the early phase of the treatment and a “catch up”
phenomenon at year 3 for both bone formation and
bone resorption.
Our finding of greater weight and BMI Z-scores in the
subjects than that of the DXA controls is consistent with
the findings of Holtkamp et al. who found a higher rate
of obesity in untreated children with ADHD than com-
munity controls [11]. We were also able to identify a
higher proportion of central fat and a higher baseline
BMD. As children approach puberty their total fat
increases, together with their proportion of central fat
[12]. However, in the subjects the proportion of central
fat decreased with time. Central body fat distribution in
children and adolescents is associated with increased
cardiovascular and metabolic risk factors [13]. The rela-
tive improvement in fat distribution experienced by the
subjects in this study contrasts with the pattern of in-
creasing abdominal fat in relation to age among adoles-
cents within their local community [12].
Our findings of initial preferential loss of central fat
are consistent with findings from a systematic review of
weight loss in adults that included 61 studies [14]. More
weight loss over longer periods showed losses of central
and peripheral fat in comparable proportions. The
changes in body composition were not specific to the
method employed for weight reduction; methods
included exercise, diet, medication and surgery. Our
study of weight loss on stimulant medication may there-
fore supply detail about the changes in body compos-
ition that might be anticipated if growing children lose
weight.
Conclusions
The effects of treatment in childhood on health in adult
life are important. The present study shows that even
relatively minor reductions in weight on stimulant
Table 4 Biochemistry results at baseline and after 3 months and 3 years
Baseline 3 months 3 years
(n=25-31) (n=17-25) (n=9-15)
Albumin (g/L) 45.1 ± 3.7 46.5 ± 3.2* 46.1 ± 4.1
Prealbumin (g/L) 0.19 ± 0.04 0.19 ± 0.04 0.20 ± 0.04
Ferritin (ug/L) 28.0 ± 12.6 33.0 ± 13.5 31.4 ± 9.4
Transferrin (g/L) 2.61± 0.30 2.59 ± 0.39 2.63 ± 0.37
Glucose (mmol/L) 4.55 ± 0.35 4.52 ± 0.39 4.57 ± 0.63
Insulin (uU/mL) 4.23 ± 2.92 3.72 ± 2.37 3.07 ± 3.22
Leptin (ng/mL) 4.45 ± 4.03 2.73 ± 2.03* 3.13 ± 1.77
Ghrelin (pmol/L) 385 ± 143 461 ± 135 378 ± 204
IGF-1 (nmol/L) 19.7 ± 7.3 18.0 ± 7.3 31.1 ± 18.0*
IGFBP-3 (ug/mL) 4.07 ± 1.08 4.02 ± 0.87 5.82 ± 2.75*
P1NP (ng/mL) 554 ± 176 458 ± 93* 620 ± 264
C telopeptides (pg/mL) 0.545 ± 0.205 0.504 ± 0.169 0.886 ± 0.518*
Osteocalcin (ng/mL) 50.9 ± 21.9 54.4 ± 13.7 80.9 ± 22.2**
Parathyroid hormone (pmol/L) 1.40 ± 0.96 1.22 ± 0.62 1.99 ± 1.22
Vitamin D (nmol/L) 67.6 ± 23.0 71.6 ± 21.4 69.1 ± 15.8
Mean ± standard deviation shown.
* p<0.05 **p<0.01 compared to baseline, paired t-test.
P1NP: propeptide of type I collagen; IGF-1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding protein 3; Vitamin D: 25-hydroxy vitamin D;
There were significant reductions in P1NP, leptin and albumin in the first 3 months. Over 3 years there were significant increases in IGF-1, IGFBP-3,
and C telopeptides and osteocalcin.
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medication can be associated not only with acute effects
on fat and bone turnover but also with long-term
changes in body composition. The improvement we
observed in the proportion of central fat for height
might reduce the long term cardiovascular and meta-
bolic risk. However, any benefit would need to be evalu-
ated in relation to the slower rate of increase in lean
tissue including bone. Further study is required to deter-
mine the effects of these changes on adult health.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AP conceived the study, recruited and enrolled the participants, was
involved in data collection and study coordination, statistical analysis and
interpretation and writing the paper. JB contributed to data collection and
statistical analysis. TM and MH carried out biochemical analysis including the
bone biomarkers. EM contributed to the data collection and study
coordination. LAB contributed to the study design and data interpretation.
GD contributed to the study design and data interpretation. All authors were
involved in revision of the manuscript and approved the final version.
Acknowledgements
The authors would like to thank the children and their families, the
Departments of Nuclear Medicine at Nepean Hospital and The Children’s
Hospital at Westmead, and Dr Jason Hort for referring patients to the study.
Funding
This research was supported by the Australian Women & Children’s Research
Foundation (OZWAC) and by the Nepean Medical Research Foundation. The
funding bodies had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; and
preparation, review, or approval of the manuscript.
Author details
1Department of Paediatrics, Sydney Medical School Nepean, The University
of Sydney, Penrith, NSW, Australia. 2Department of Nuclear Medicine, The
Children’s Hospital at Westmead, Sydney, NSW, Australia. 3Ageing Bone
Research Program, Sydney Medical School Nepean, The University of Sydney,
Penrith, NSW, Australia. 4Central Laboratory of Clinical Pathology, Central
Hospital of Bolzano, Bolzano, Italy. 5University of Sydney Discipline of
Paediatrics and Child Health, The Children’s Hospital at Westmead, Sydney,
NSW, Australia.
Received: 28 August 2012 Accepted: 30 November 2012
Published: 5 December 2012
References
1. Faraone SV, Biederman J, Morley CP, Spencer TJ: Effect of stimulants on
height and weight: a review of the literature. J Am Acad Child Adolesc
Psychiatry 2008, 47(9):994–1009.
2. Lisska MC, Rivkees SA: Daily methylphenidate use slows the growth of
children: a community based study. J Pediatr Endocrinol Metab 2003,
16(5):711–718.
3. Poulton A: Growth on stimulant medication; clarifying the confusion: a
review. Arch Dis Child 2005, 90(8):801–806.
4. Poulton A, Cowell CT: Slowing of growth in height and weight on
stimulants: a characteristic pattern. J Paediatr Child Health 2003,
39(3):180–185.
5. American Psychiatric Association: Diagnostic and statistical manual of mental
disorders IV. Washington, DC: American Psychiatric Association; 1994.
6. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J,
Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S:
Practice parameter for the use of stimulant medications in the treatment
of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry
2002, 41(2 Suppl):26S–49S.
7. Pelham W, Milich R, Murphy D, Murphy H: Normative data on the IOWA
Conners teacher rating scale. J Clin Child Psychology 1989, 18(3):259–262.
8. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z,
Wei R, Curtin LR, Roche AF, Johnson CL: 2000 CDC Growth Charts for the
United States: methods and development. Vital Health Stat 11 2002,
(246):1–190.
9. Tsang T, Briody J, Kohn M, Chow C, Singh M: Abdominal fat assessment in
adolescents using dual-energy X-ray absorptiometry. J Pediatr Endocrinol
Metab 2009, 22(9):781.
10. Lahat E, Weiss M, Ben-Shlomo A, Evans S, Bistritzer T: Bone mineral density
and turnover in children with attention-deficit hyperactivity disorder
receiving methylphenidate. J Child Neurol 2000, 15(7):436–439.
11. Holtkamp K, Konrad K, Müller B, Heussen N, Herpertz S, Herpertz-Dahlmann B,
Hebebrand J: Overweight and obesity in children with attention-deficit/
hyperactivity disorder. Int J Obes 2004, 28(5):685–689.
12. Garnett SP, Cowell CT, Baur LA, Shrewsbury VA, Chan A, Crawford D,
Salmon J, Campbell K, Boulton TJ: Increasing central adiposity: the
Nepean longitudinal study of young people aged 7–8 to 12–13 y.
Int J Obes 2005, 29(11):1353–1360.
13. Schmidt MD, Dwyer T, Magnussen CG, Venn AJ: Predictive associations
between alternative measures of childhood adiposity and adult
cardio-metabolic health. Int J Obes 2011, 35:38–45.
14. Chaston TB, Dixon JB: Factors associated with percent change in visceral
versus subcutaneous abdominal fat during weight loss: findings from a
systematic review. Int J Obes 2008, 32(4):619–628.
doi:10.1186/1687-9856-2012-30
Cite this article as: Poulton et al.: Weight loss on stimulant medication:
how does it affect body composition and bone metabolism? – A
prospective longitudinal study. International Journal of Pediatric
Endocrinology 2012 2012:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Poulton et al. International Journal of Pediatric Endocrinology 2012, 2012:30 Page 9 of 9
http://www.ijpeonline.com/content/2012/1/30
